Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT07038096RecruitingPhase 1/Phase 2
Testing ZG006 and ZG005 for lung and neuroendocrine cancers
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Guanzhou, GuangdongAges 18–70 - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–90 - NCT07038824RecruitingPhase 1/Phase 2
A study of ENTR-601-45 for Duchenne MD (exon 45 skipping)
This trial tests an experimental drug called ENTR-601-45 for people with Duchenne muscular dystrophy that can be treated with 'exon 45 skipping.' The goal is to see if it's safe and helps improve muscle function. It's for males between 4 and 20 who can still walk and have enough arm strength.
GhentAges 4–20 - NCT07035769RecruitingPhase 1
Debio 1453P safety study in healthy adults
This trial tests an experimental oral drug, Debio 1453P, for the first time in people. Healthy adults can take part to see if the drug is safe and how the body processes it.
EdegemAges 18–55 - NCT07037433RecruitingPhase 3
Heart protection study for people with heart disease and overweight
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Daphne, AlabamaAges 45–99 - NCT07037862RecruitingPhase 1/Phase 2
Study of ENTR-601-44 for Duchenne muscular dystrophy (exon 44 skipping)
This trial tests a new medicine called ENTR-601-44 for people with Duchenne muscular dystrophy whose genetic mutation can be treated by skipping a part of the gene called exon 44. The goal is to see if it is safe and helps with muscle function.
GhentAges 4–20 - NCT07039110Recruiting
Risankizumab for psoriasis: quality of life study
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
Calgary, AlbertaAges 18 years+ - NCT07038200RecruitingPhase 3
Study of Del-brax (AOC 1020) for People with FSHD
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
Orange, CaliforniaAges 16–70 - NCT07036510RecruitingPhase 1/Phase 2
Safety and effectiveness of a timolol eye implant for glaucoma patients having cataract surgery
This trial tests a sustained-release implant that delivers timolol, a medicine to lower eye pressure, for people with glaucoma or high eye pressure who are also having cataract surgery. The implant is placed during surgery and may provide long-term pressure control without daily eye drops.
Panama CityAges 40 years+ - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT07040930RecruitingPhase 1
Testing the safety of GenSci120 in healthy adults
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07040046RecruitingPhase 1
Study of HS-10542 in healthy volunteers
This trial tests an investigational drug, HS-10542, in healthy adults to see how it is processed by the body and to check for side effects. You must be willing to receive two vaccines before the study starts.
Qingdao, ShandongAges 18–64 - NCT07042009Recruiting
Nutrition resources for new milk donors
This trial tests if providing nutrition information helps new mothers who donate milk. It's designed for donors at one specific hospital milk bank.
ChesterAges 18 years+ - NCT07030790RecruitingPhase 1
Single dose study of KLA480 in healthy volunteers
This trial tests a single dose of KLA480 in healthy adults to see how the body processes it. It may help researchers understand the drug's safety and potential benefits.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT07033026RecruitingPhase 2
Study of NGM120 for weight loss in colorectal cancer
This study tests an experimental drug called NGM120 for people with colorectal cancer who are losing weight (a condition called cancer cachexia). It is a placebo-controlled trial, meaning some participants will receive the drug and some will receive a placebo, to see if the drug helps stop or reverse this weight loss.
Los Angeles, CaliforniaAges 18 years+ - NCT07027514RecruitingPhase 1
Combination treatment for advanced lung cancer
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
Coral Gables, FloridaAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07032662RecruitingPhase 2
Study of imeroprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
Tucson, ArizonaAges 18 years+ - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.